Hiroyuki Okuzawa is the Chief Executive Officer and Representative Director of Daiichi Sankyo Company, a global pharmaceutical and healthcare organisation known for its innovative medicines competing on an international scale. He was appointed CEO effective April 1, 2025, after serving as President and Chief Operating Officer, and brings nearly four decades of experience with the company since joining in 1986. Okuzawa has played a pivotal role in advancing Daiichi Sankyo’s five‑year business plan (FY2021–2025), which has overseen the rapid global expansion of the company’s oncology business and strengthened its position in antibody‑drug conjugate (ADC) technology, contributing to the success of precision cancer medicines that have had significant clinical impact.
Under the broader strategic framework Okuzawa now leads, Daiichi Sankyo continues to build on its established strengths in oncology and other high‑need therapeutic areas while preparing for its next five‑year plan toward its 2035 vision of becoming an innovative global healthcare company. His leadership emphasises leveraging science and technology to enrich patient quality of life, fostering a collaborative global culture, and supporting long‑term growth in research, development and global access to new therapies.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
